Jubilant Biosys, a Bangalore-based subsidiary of Jubilant Organosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals to develop a portfolio of oncology targets with a focus on delivering preclinical candidates for joint clinical development.

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization. In the initial three-year agreement, Jubilant will receive research funding and success-based development milestones, as well as royalties on the successful commercialization of the compounds developed.

Mr. Shyam Bhartia, chairman and managing director, and Mr. Hari S Bhartia, co-chairman and managing director, Jubilant Organosys, said, "We are pleased to announce this collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo's expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant's mission to be India's largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care."

Dr. Ivan Gergel, M.D., executive vice president of R&D at Endo Pharmaceuticals commented, "We are excited about this opportunity with Jubilant. We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients."